

# Andrew W Stephens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/25196/publications.pdf>

Version: 2024-02-01

26  
papers

1,576  
citations

394421

19  
h-index

552781

26  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1762  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tau deposition patterns are associated with functional connectivity in primary tauopathies. <i>Nature Communications</i> , 2022, 13, 1362.	12.8	34
2	Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer's Disease. <i>Biomolecules</i> , 2022, 12, 458.	4.0	9
3	Quantification of amyloid PET for future clinical use: a state-of-the-art review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3508-3528.	6.4	34
4	Early detection of amyloid load using 18F-florbetaben PET. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 67.	6.2	26
5	Cortical [ <sup>18</sup> F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. <i>Movement Disorders</i> , 2021, 36, 2104-2115.	3.9	46
6	Binding characteristics of [ <sup>18</sup> F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2957-2972.	4.3	30
7	Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3872-3885.	6.4	22
8	Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [18F]PI-2620. <i>Frontiers in Neurology</i> , 2021, 12, 684523.	2.4	11
9	[ <sup>18</sup> F]PI-2620 Lead Optimization Highlights the Importance of Off-Target Assays to Develop a PET Tracer for the Detection of Pathological Aggregated Tau in Alzheimer's Disease and Other Tauopathies. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12808-12830.	6.4	11
10	Structure-activity relationship around PI-2620 highlights the importance of the nitrogen atom position in the tricyclic core. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 52, 116528.	3.0	6
11	Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of [ <sup>18</sup> F]PI-2620 PET for the Assessment of Tau Deposits in the Human Brain. <i>Journal of Nuclear Medicine</i> , 2020, 61, 920-927.	5.0	24
12	Tau PET imaging with [ <sup>18</sup> F]PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 911-919.	5.0	122
13	Discovery of 2-(4-(2-fluoroethoxy)piperidin-1-yl)-9-methyl-9H-pyrrolo[2,3-b:4,5-c']dipyridine ([ <sup>18</sup> F]PI-2014) as PET tracer for the detection of pathological aggregated tau in Alzheimer's disease and other tauopathies. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112615.	5.5	5
14	Assessment of [ <sup>18</sup> F]PI-2620 as a Biomarker in Progressive Supranuclear Palsy. <i>JAMA Neurology</i> , 2020, 77, 1408.	9.0	145
15	Converging evidence for a gray-zone of amyloid burden and its relevance. <i>Alzheimer's and Dementia</i> , 2020, 16, e044786.	0.8	4
16	Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2911-2922.	6.4	36
17	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, 750-758.	0.8	29
18	Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2178-2189.	6.4	148

#	ARTICLE	IF	CITATIONS
19	Comparison of <sup>18</sup> F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL approaches: Validation against histopathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 807-816.	0.8	50
20	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimer's and Dementia</i> , 2019, 15, 388-399.	0.8	37
21	Validation of Noninvasive Tracer Kinetic Analysis of <sup>18</sup> F-Florbetaben PET Using a Dual-Time-Window Acquisition Protocol. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1104-1110.	5.0	27
22	Added value of <sup>18</sup> F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study. <i>Alzheimer's and Dementia</i> , 2018, 14, 293-305.	0.8	48
23	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. <i>JAMA Neurology</i> , 2018, 75, 1062.	9.0	102
24	<sup>18</sup> F-Florbetaben PET beta-amyloid binding expressed in Centiloids. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2053-2059.	6.4	87
25	Impact of Training Method on the Robustness of the Visual Assessment of <sup>18</sup> F-Florbetaben PET Scans: Results from a Phase-3 Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 900-906.	5.0	79
26	Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study. <i>Alzheimer's and Dementia</i> , 2015, 11, 964-974.	0.8	400